Genotypes and haplotypes in the 3' untranslated region of the HLA-G gene and their association with clinical outcome of hematopoietic stem cell transplantation for beta-thalassemia.

Polymorphisms in the 3' untranslated region (3'UTR) of HLA-G, an important player in immunological tolerance, could be involved in post-transcriptional expression control, and their association with different clinical immune-related conditions including autoimmunity and transplantation is of mounting interest. Most studies have focused on a 14 base pair (bp) insertion/deletion (ins/del), while additional single-nucleotide polymorphisms (SNPs) in the HLA-G 3'UTR have been described but not extensively investigated for their clinical relevance. Here we have comparatively studied the association between 3'UTR haplotypes of HLA-G, or the 14 bp ins/del, with clinical outcome of HLA-identical sibling hematopoietic stem cell transplantation (HSCT) in 147 Middle Eastern beta-thalassemia patients. Sequence based typing of 3'UTR HLA-G polymorphisms in the patients and in 102 healthy Italian blood donors showed strong linkage disequilibrium between the 14 bp ins/del and five 3'UTR SNPs, which together could be arranged into eight distinct haplotypes based on expectation-maximization studies, with four predominant haplotypes (UTRs1-4). After HSCT, we found a moderate though not significant association between the presence of UTR-2 in double dose and protection from acute graft versus host disease (hazard ratio (HR) 0.45, 95% confidence intervals (CI): 0.14-1.45; P = 0.18), an effect that was also seen when the corresponding 14 bp ins/ins genotype was considered alone (HR 0.42, 95% CI: 0.16-1.06; P = 0.07). No association was found with rejection or survival. Taken together, our data show that there is no apparent added value of considering entire 3'UTR HLA-G haplotypes for risk prediction after allogeneic HSCT for beta-thalassemia.

[1]  P. Chiusolo,et al.  Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia , 2012, Bone Marrow Transplantation.

[2]  E. Donadi,et al.  Human leukocyte antigen-G 3' untranslated region polymorphisms are associated with better kidney allograft acceptance. , 2012, Human immunology.

[3]  P. Chiusolo,et al.  The role of HLA–G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis , 2012, Bone Marrow Transplantation.

[4]  E. Donadi,et al.  A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. , 2011, Molecular biology and evolution.

[5]  V. Rao,et al.  The 14-bp deletion in the HLA-G gene indicates a low risk for acute cellular rejection in heart transplant recipients. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  S. Gregori,et al.  Dendritic cells in networks of immunological tolerance. , 2011, Tissue antigens.

[7]  N. Rouas-Freiss,et al.  The role of HLA-G in immunity and hematopoiesis , 2011, Cellular and Molecular Life Sciences.

[8]  E. Angelucci Hematopoietic stem cell transplantation in thalassemia. , 2010, Hematology. American Society of Hematology. Education Program.

[9]  E. Donadi,et al.  Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association , 2010, Cellular and Molecular Life Sciences.

[10]  A. Klimczak,et al.  Association of the HLA‐G gene polymorphism with multiple sclerosis in a Polish population , 2010, International journal of immunogenetics.

[11]  E. Donadi,et al.  The genetic structure of 3′untranslated region of the HLA-G gene: polymorphisms and haplotypes , 2010, Genes and Immunity.

[12]  S. Giuliatti,et al.  In silico analysis of microRNAS targeting the HLA-G 3' untranslated region alleles and haplotypes. , 2009, Human immunology.

[13]  M. Larsen,et al.  Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. , 2009, Human immunology.

[14]  A. Delgado-Cañedo,et al.  Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus , 2009, Lupus.

[15]  J. Chies,et al.  Tolerance versus immune response -- microRNAs as important elements in the regulation of the HLA-G gene expression. , 2009, Transplant immunology.

[16]  A. Lin,et al.  The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. , 2008, Tissue antigens.

[17]  M. Rubini,et al.  HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. , 2008, Tissue antigens.

[18]  Philippe Moreau,et al.  HLA-G: from biology to clinical benefits. , 2008, Trends in immunology.

[19]  J. Lubiński,et al.  HLA-G polymorphism in a Polish population and reproductive failure. , 2007, Tissue antigens.

[20]  E. Donadi,et al.  Frequency of insertion/deletion polymorphism in exon 8 of HLA-G and kidney allograft outcome. , 2007, Tissue antigens.

[21]  C. Carcassi,et al.  The human leucocyte antigen‐G 14‐basepair polymorphism correlates with graft‐versus‐host disease in unrelated bone marrow transplantation for thalassaemia , 2007, British journal of haematology.

[22]  Carole Ober,et al.  Allele-specific targeting of microRNAs to HLA-G and risk of asthma. , 2007, American journal of human genetics.

[23]  Laurent Excoffier,et al.  Arlequin (version 3.0): An integrated software package for population genetics data analysis , 2005, Evolutionary bioinformatics online.

[24]  X. J. Chen,et al.  Association of the maternal 14-bp insertion polymorphism in the HLA-G gene in women with recurrent spontaneous abortions. , 2006, Tissue antigens.

[25]  C. Ober,et al.  Evidence of balancing selection at the HLA-G promoter region. , 2005, Human molecular genetics.

[26]  Wei Zhang,et al.  Tolerization of dendritic cells by HLA‐G , 2005, European journal of immunology.

[27]  S. Agrawal,et al.  Role of 14-bp deletion in the HLA-G gene in the maintenance of pregnancy. , 2004, Tissue antigens.

[28]  O. Christiansen,et al.  Association between human leukocyte antigen-G genotype and success of in vitro fertilization and pregnancy outcome. , 2004, Tissue antigens.

[29]  Eunkyung Kim,et al.  Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. , 2004, Biochemical and biophysical research communications.

[30]  S. Kuersten,et al.  The power of the 3′ UTR: translational control and development , 2003, Nature Reviews Genetics.

[31]  T. Hviid,et al.  HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels , 2003, Immunogenetics.

[32]  O. Christiansen,et al.  HLA-G polymorphisms in couples with recurrent spontaneous abortions. , 2002, Tissue antigens.

[33]  I. Sargent,et al.  HLA-G suppresses proliferation of CD4(+) T-lymphocytes. , 2000, Journal of reproductive immunology.

[34]  J. Dausset,et al.  HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. , 1999, International immunology.

[35]  J. Dausset,et al.  The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Andreani,et al.  Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. , 1996, Blood.

[37]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.